In a extremely uncommon transfer for a usually buttoned-up regulatory company, a senior official with the US Food and Drug Administration held a name with reporters Thursday to defend the company’s recent choice on an experimental drugs, calling it a “failed therapy” and railing towards outdoors critics.
The name targeted on the FDA’s decision to ask for a further scientific trial from the biotechnology firm UniQure earlier than greenlighting it to use for approval of its gene remedy for Huntington’s illness, a deadly neurodegenerative dysfunction. Patients and the corporate had hoped the remedy might transfer into an FDA assessment primarily based on current proof, a hope that was dashed Monday.
But the regulator, who spoke on the situation of anonymity, additionally attacked outdoors scientists who serve on advisory committees for the company, saying they “do not do their homework” and could also be motivated by monetary conflicts of curiosity. The official moreover singled out Dr. Janet Woodcock, a retired FDA veteran who known as the UniQure choice “truly evil” in an interview with the New York Times this week.
“Dr. Woodcock is an esteemed regulator,” the official mentioned, “and as such, there are many commenters who I don’t expect better from, but Dr. Woodcock, I do expect better from.”
Woodcock declined to remark to NCS on Thursday.
The FDA name represented a tense crescendo in a sequence of strikes which have raised questions on whether or not the regulator is altering goalposts in the case of drug approvals.
Numerous corporations have claimed that recent actions by the regulator ran counter to prior steering, slowing approvals of new medicines even because the company has been touting methods it plans to hurry up the method.
Last month, the company confronted a firestorm of criticism for initially refusing to assessment a assessment software from Moderna for an mRNA flu vaccine earlier than finally accepting the applying with some changes. It held an analogous media name then with a special senior official to defend itself.
The FDA has additionally been criticized for recent strikes on uncommon illness medicine from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals, Regenxbio and others.
On Thursday, the FDA official disputed news coverage and statements from UniQure suggesting that the company is requiring the corporate run a scientific trial involving a pretend 10-hour mind surgical procedure as a placebo management for the gene therapy, which is given as a one-time infusion administered straight into the mind in an eight- to 10-hour process.
“Does the sham intervention require 10 hours of anesthesia? No, it does not,” the official advised reporters. “It takes under 30 minutes of anesthesia. … Did FDA ask UniQure to drill holes in skulls? No, they just need to make one to three nicks in the scalp.”
The official mentioned the company requires placebo-controlled trials to make sure that the product is just not “snake oil” and argued that it’s longstanding FDA coverage to require them for Huntington’s illness therapies.
UniQure had hoped to make a submission to the FDA utilizing information from an earlier trial that instructed its remedy slowed illness development in contrast with an exterior management group made up of individuals with Huntington’s who weren’t within the examine.
The communications with the company happened in a routine sequence of interactions wherein the FDA offered steering on whether or not UniQure might submit an software for approval with current information. The firm has called the company’s new posture “a drastic change” from steering it offered in late 2024.
UniQure declined to remark Thursday, however earlier within the week its chief government advised STAT News in response to feedback from an FDA official that the corporate was “incredulous that a senior FDA official is speaking to the media and communicating things that in many respects, have never been communicated to us.”